Funded Biomarker Testing
69 items
Reflex testing on newly diagnosed invasive gastroesophageal adenocarcinomas.
Funded Biomarker Disease Site: Stomach
Biomarker: PD-L1
Testing Method:Immunohistochemistry (IHC)
Testing Site: London Health Sciences Centre, Mount Sinai Hospital, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Unity Health - St. Michael's Hospital, University Health Network, William Osler Health System
Reflex testing on newly diagnosed sebaceous neoplasms.
Funded Biomarker Disease Site: Skin
Biomarker: MLH1, MSH2, MSH6, PMS2
Testing Method:Immunohistochemistry (IHC)
Testing Site: Hamilton Health Sciences, Health Sciences North, Kingston Health Sciences Centre, London Health Sciences Centre, Markham Stouffville Hospital (Oak Valley Health), Mount Sinai Hospital, St. Joseph's Healthcare Hamilton, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Trillium Health Partners, Unity Health - St. Michael's Hospital, University Health Network, William Osler Health System
Reflex testing on newly diagnosed sebaceous tumours.
Funded Biomarker Disease Site: Ocular
Biomarker: MLH1, MSH2, MSH6, PMS2
Testing Method:Immunohistochemistry (IHC)
Testing Site: Hamilton Health Sciences, Health Sciences North, Kingston Health Sciences Centre, London Health Sciences Centre, Mount Sinai Hospital, St. Joseph's Healthcare Hamilton, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Trillium Health Partners, Unity Health - St. Michael's Hospital, University Health Network, William Osler Health System
Reflex testing on newly diagnosed tumours with adrenal cortical carcinoma.
Funded Biomarker Disease Site: Adrenal Gland
Biomarker: MLH1, MSH2, MSH6, PMS2
Testing Method:Immunohistochemistry (IHC)
Testing Site: Hamilton Health Sciences, Kingston Health Sciences Centre, London Health Sciences Centre, Mount Sinai Hospital, St. Joseph's Healthcare Hamilton, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Trillium Health Partners, University Health Network, William Osler Health System
Reflex testing on newly diagnosed tumours with advanced/metastatic prostate carcinoma.
Funded Biomarker Disease Site: Prostate
Biomarker: ATM, BRCA1, BRCA2, PALB2
Testing Method:Panel
Testing Site: Hamilton Health Sciences, Kingston Health Sciences Centre, London Health Sciences Centre, Mount Sinai Hospital, St. Joseph's Healthcare Hamilton, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Trillium Health Partners, University Health Network, William Osler Health System
Reflex testing on newly diagnosed tumours with advanced/metastatic prostate carcinoma.
Funded Biomarker Disease Site: Prostate
Biomarker: AR
Testing Method:Immunohistochemistry (IHC)
Testing Site: Hamilton Health Sciences, Kingston Health Sciences Centre, London Health Sciences Centre, Mount Sinai Hospital, St. Joseph's Healthcare Hamilton, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Trillium Health Partners, University Health Network, William Osler Health System
Reflex testing on newly diagnosed tumours with advanced/metastatic small bowel carcinoma.
Funded Biomarker Disease Site: Small Bowel
Biomarker: MLH1, MSH2, MSH6, PMS2
Testing Method:Immunohistochemistry (IHC)
Testing Site: Hamilton Health Sciences, Health Sciences North, Kingston Health Sciences Centre, London Health Sciences Centre, Markham Stouffville Hospital (Oak Valley Health), Mount Sinai Hospital, St. Joseph's Healthcare Hamilton, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Trillium Health Partners, Unity Health - St. Michael's Hospital, University Health Network, William Osler Health System
Reflex testing on newly diagnosed tumours with advanced/metastatic urothelial carcinoma.
Funded Biomarker Disease Site: Bladder/ Urothelial
Biomarker: FGFR2, FGFR3
Testing Method:Panel
Testing Site: Hamilton Health Sciences, Kingston Health Sciences Centre, London Health Sciences Centre, Mount Sinai Hospital, St. Joseph's Healthcare Hamilton, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Trillium Health Partners, University Health Network, William Osler Health System
Reflex testing on newly diagnosed tumours with invasive biliary/gallbladder adenocarcinoma.
Funded Biomarker Disease Site: Hepatobiliary
Biomarker: MLH1, MSH2, MSH6, PMS2
Testing Method:Immunohistochemistry (IHC)
Testing Site: Hamilton Health Sciences, Health Sciences North, Kingston Health Sciences Centre, London Health Sciences Centre, Markham Stouffville Hospital (Oak Valley Health), Mount Sinai Hospital, North York General Hospital, St. Joseph's Healthcare Hamilton, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Trillium Health Partners, Unity Health - St. Michael's Hospital, University Health Network, William Osler Health System
Reflex testing on newly diagnosed tumours with invasive carcinoma of the pancreas.
Funded Biomarker Disease Site: Pancreas
Biomarker: MLH1, MSH2, MSH6, PMS2
Testing Method:Immunohistochemistry (IHC)
Testing Site: Hamilton Health Sciences, Health Sciences North, Kingston Health Sciences Centre, London Health Sciences Centre, Markham Stouffville Hospital (Oak Valley Health), Mount Sinai Hospital, North York General Hospital, St. Joseph's Healthcare Hamilton, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Trillium Health Partners, Unity Health - St. Michael's Hospital, University Health Network, William Osler Health System
Reflex testing on newly diagnosed tumours with invasive colorectal cancer.
Funded Biomarker Disease Site: Colorectal
Biomarker: MLH!, MSH2, MSH6, PMS2
Testing Method:Immunohistochemistry (IHC)
Testing Site: Hamilton Health Sciences, Health Sciences North, Kingston Health Sciences Centre, London Health Sciences Centre, Markham Stouffville Hospital (Oak Valley Health), Mount Sinai Hospital, North York General Hospital, Southlake Regional Health Centre, St. Joseph's Healthcare Hamilton, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Trillium Health Partners, Unity Health - St. Michael's Hospital, University Health Network, William Osler Health System
Reflex testing on newly diagnosed tumours with invasive endometrial cancer.
Funded Biomarker Disease Site: Endometrium
Biomarker: MLH1, MSH2, MSH6, PMS2
Testing Method:Immunohistochemistry (IHC)
Testing Site: Hamilton Health Sciences, Health Sciences North, Kingston Health Sciences Centre, London Health Sciences Centre, Markham Stouffville Hospital (Oak Valley Health), Mount Sinai Hospital, St. Joseph's Healthcare Hamilton, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Trillium Health Partners, Unity Health - St. Michael's Hospital, University Health Network, William Osler Health System